Business
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today presented new global, real-world, patient-centric data, including data from a study assessing the impacts on quality of life that developmental and epileptic encephalopathies (DEEs) have on individuals and caregivers, as well as the impact of living with prolonged seizures on patients and their caregivers. The company is presenting 21 abstracts in total from its innovative neurology portfolio (14 epilepsy and 7 rare disease
About this update from United Community Banks, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Substantial impact of sleep disturbances: New interim caregiver survey results found that a quarter of patients with developmental and epileptic encephalopathies (DEEs) experienced daily sleep disturbances, leading to a negative impact on activities of daily living and communication.1","length":285,"tagName":"p"}]},{"val":[{"type":"text","content":"Impact of prolonged seizures: Results from global real-world data illustrate the impacts of prolonged seizures on both people living with epilepsy and their caregivers, with 88% and 96%, respectively, reporting that seizures impacted their ability to perform normal daily activities.2,3","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"Benefits of persistence: Claims analysis data evaluating treatment persistence with FINTEPLA®4 (fenfluramine) for people in the U.S. living with Lennox-Gastaut syndrome (LGS) show reductions in healthcare resource utilization and antiseizure medication claims for patients with treatment persistence at 6 and 12 months.5","length":325,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":896,"olType":false},{"type":"text","content":"ATLANTA, April 15, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today presented new global, real-world, patient-centric data, including data from a study assessing the impacts on quality of life that developmental and epileptic encephalopathies (DEEs) have on individuals and caregivers, as well as the impact of living with prolonged seizures on patients and their caregivers. The company is presenting 21 abstracts in total from its innovative neurology portfolio (14 epilepsy and 7 rare disease including 6 myasthenia gravis (MG) abstracts) at the American Academy of Neurology (AAN) 2026 Annual Meeting (April 18-22, 2026).","length":674,"tagName":"p"},{"type":"image","alt":"FINTEPLA® (fenfluramine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older. (PRNewsfoto/UCB)","displaySize":"","headline":null,"caption":"FINTEPLA® (fenfluramine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in pa...